Alzamend Neuro (ALZN) Soars 18.83% on Phase II Trial Launch

Alzamend Neuro (ALZN) has seen a significant surge in its stock price, with an intraday gain of 18.83%, reaching its highest level since August 2024. This marks the second consecutive day of decline, following a remarkable 535.16% increase over the past two days.

The strategy of buying ALZN shares after they reached a recent high and holding for 1 week resulted in a significant loss. Over the past 5 years, the portfolio experienced a maximum drawdown of 49.8% from May 12, 2024, to May 12, 2025, with a recovery time of 12 months. The portfolio generated a return of -17.95% per year, with 107 out of 160 or 66.88% of months negative. The best month for the portfolio was May 2024, with a return of 24.02%, while the worst month was May 2025, with a return of -17.95%. The strategy underperformed the benchmark, which generated a return of 13.81% per year, with 111 out of 160 or 69.38% of months positive.

Alzamend Neuro has made a significant stride in its clinical development efforts. The company has initiated the first of five Phase II clinical trials for its compound AL001, focusing on healthy human participants. This trial is designed to evaluate the effectiveness of AL001 in delivering lithium to the brain compared to currently available lithium products. AL001 is engineered to enhance safety and efficacy by improving brain targeting and reducing systemic side effects, which could potentially eliminate the need for lithium therapeutic drug monitoring (TDM).

This advancement is particularly noteworthy as it offers a safer and more effective treatment option for conditions such as Alzheimer's, bipolar disorder, major depressive disorder, and post-traumatic stress disorder. The initiation of these trials and the potential benefits of AL001 have likely contributed to the recent surge in ALZN's stock price, reflecting investor optimism about the company's innovative approach to lithium therapy.